http://www.fresenius.com en-us Mon, 05 Aug 2019 00:00:00 +0200 Mon, 05 Aug 2019 00:00:00 +0200 Mon, 05 Aug 2019 08:00:00 +0100 <![CDATA[Fresenius Helios expands preventive medicine offering]]> Fresenius Helios has opened a new Helios Prevention Center in Berlin, as the company continues the expansion of its occupational medicine activities into a standalone business area. The modern, 440-square-meter (4,700-square-foot) center in the heart of Germany’s capital offers comprehensive check-ups from a single source. HCP patients are accompanied throughout the check-up by their own personal physician, and do not have to search for the right department for their next test, deal with different contact persons, or face long waiting times. And if a test turns up something requiring medical treatment, the patient has direct access to the Helios healthcare network and an exclusive hotline for making appointments with specialists.

]]>
Tue, 30 Jul 2019 08:00:00 +0100 <![CDATA[Fresenius raises Group sales growth guidance after good second quarter ]]> Good organic sales growth across all business segments - Growth investments well on track - Fresenius Kabi successfully launched first biosimilar in Europe; continued excellent growth in Emerging Markets - Fresenius Helios showing strong organic sales growth in Germany and enters successfully Colombian hospital market - Fresenius Medical Care’s strategy reinforced by U.S. government’s plans for changes of kidney disease care

]]>
Mon, 08 Jul 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi launches IV Drug in the U.S.]]> Fresenius Kabi launches Levothyroxine Sodium Injection in the U.S. It is the first, and only, pre-mixed solution of this medication currently available in the U.S.

]]>
Wed, 19 Jun 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi launches IV Drug in the U.S.]]> Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection is the latest addition to the company´s growing anesthesia and analgesia portfolio.

]]>
Tue, 11 Jun 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi launches Neostigmine in prefilled syringes in the U.S.]]> Neostigmine is now available in the company’s Simplist® ready-to-administer prefilled syringes, expanding the company´s analgesia and anesthesia portfolio.

]]>
Thu, 23 May 2019 08:00:00 +0100 <![CDATA[S&P upgrades Fresenius to BBB with stable outlook ]]> Standard & Poor’s has revised Fresenius’ corporate credit rating to BBB with a stable outlook from BBB- with a positive outlook. Fresenius is rated investment grade by the three leading rating agencies Standard & Poor’s (BBB/stable), Moody's (Baa3/stable) and Fitch (BBB-/stable).

]]>
Fri, 03 May 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi launches biosimilar adalimumab IDACIO® in Germany]]> Fresenius Kabi is launching its first biosimilar in Germany following the European Commission (EC) granting marketing authorization for IDACIO® for all indications of the reference medicine in the areas of rheumatology, gastroenterology and dermatology.

]]>
Thu, 02 May 2019 08:00:00 +0100 <![CDATA[Fresenius makes solid start to 2019 and confirms Group guidance ]]> Fresenius makes solid start to 2019 and confirms Group guidance - Fresenius Kabi with continued good growth in Q1/19 - Helios Germany stabilized; Helios Spain with continued dynamic growth - Group guidance confirmed despite expected earnings dilution from NxStage

]]>
Tue, 30 Apr 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi launches Glycopyrrolate in prefilled syringes in the U.S.]]> Glycopyrrolate is now available in the company’s Simplist™ ready-to-administer prefilled syringes, expanding the company´s analgesia and anesthesia portfolio. It is the first FDA-approved manufacturer-supplied ready-to-administer prefilled syringe for this medication in the U.S. 

]]>
Tue, 09 Apr 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi launches Adenosine in prefilled syringes in the U.S.]]> Adenosine, a drug used in critical care settings, is now available in the United States in the company’s Simplist™ ready-to-administer prefilled syringes. Fresenius Kabi now offers the broadest portfolio of Adenosine Injection.

]]>
Wed, 03 Apr 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi receives European Commission approval for adalimumab biosimilar IDACIO®]]> The European Commission (EC) granted Fresenius Kabi the marketing authorization for IDACIO®, an adalimumab biosimilar, for all indications of the reference medicine. With this EC approval, IDACIO® is the first approved molecule of the Fresenius Kabi biosimilars portfolio.

]]>
Tue, 19 Mar 2019 08:00:00 +0100 <![CDATA[Fresenius Helios and Marburger Bund agree on collective labor agreement]]> Helios Germany and the doctors' union Marburger Bund have agreed on a collective labor agreement for about 5,400 physicians in 34 Helios hospitals. It applies to the hospitals included in the Helios Group collective labor agreement. With effect from 1 January 2019, the base salary will increase by 2.5 percent. A further increase of 2.5 percent will follow on January 1, 2020. Salaries will thus increase by a total of 5 percent. This is in line with Fresenius Group's expectations.

]]>
Fri, 15 Mar 2019 08:00:00 +0100 <![CDATA[Fresenius Helios holds topping-out ceremony for new hospital building in Wiesbaden]]> Fresenius Helios held the topping-out ceremony today for the new main building at Helios HSK hospital in the German city of Wiesbaden, near Frankfurt. The seven-story structure, with almost 100,000 square meters (about 1 million square feet) of floor space, is being erected beside the existing clinic. It will have 22 operating rooms, about 1,000 beds, and a design that significantly reduces distances and waiting times for patients. Helios is investing about €200 million in the new building, while the state of Hesse is contributing €68 million. Completion is scheduled for 2021.

]]>
Wed, 20 Feb 2019 08:00:00 +0100 <![CDATA[Fresenius reports 15th consecutive record year – Significant investments into medium-term growth in FY/18 and FY/19 – Healthy medium-term growth targets]]> Delivered on FY/18 Group targets; Fresenius Kabi to show continued growth; Helios Germany impacted by regulatory changes and initiatives to secure medium-term growth; Helios Spain to show continuous dynamic growth; 26th consecutive dividend increase proposed; Healthy growth targets for 2020 – 2023; consistent with expectations from December 2018

]]>
Tue, 12 Feb 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi launches IV Drug in the U.S.]]> Methocarbamol Injection is the newest addition to the company´s anesthesia and analgesia portfolio.

]]>
Fri, 01 Feb 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi receives positive CHMP opinion for MSB11022, a biosimilar candidate of adalimumab]]> Fresenius Kabi announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion, recommending marketing authorization for MSB11022 a biosimilar candidate of Humira® (adalimumab)*. The European Commission (EC) will now decide on the approval of MSB11022 which is expected in Q2/ 2019.
*Humira® is a registered trademark of AbbVie Biotechnology Ltd.

]]>
Tue, 29 Jan 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi launches IV Drug in the U.S.]]> Leucovorin Calcium is the newest addition to the company’s large oncology portfolio.

]]>
Mon, 14 Jan 2019 08:00:00 +0100 <![CDATA[Fresenius Vamed adds new resort to network in Austria]]> VAMED Vitality World has taken over operation of a health resort in Austria’s Styria state. Operating under the new name of Spa Resort Styria in the town of Bad Waltersdorf, near Graz, the resort will offer health tourism for adults. Fresenius Vamed is the market leader in Austria, with about 3.2 million annual visitors to the company’s eight thermal spas and health resorts.

]]>
Thu, 10 Jan 2019 08:00:00 +0100 <![CDATA[Fresenius successfully places €1.0 billion in notes]]> Fresenius today successfully placed notes in two tranches with an aggregate volume of €1.0 billion.

]]>
Fri, 14 Dec 2018 08:00:00 +0100 <![CDATA[Fresenius wins award for compensatory time account calculator]]> Fresenius has been awarded the HR Excellence Award 2018 in the Compensation & Benefits category for the global healthcare group’s compensatory time account calculator. This calculator enables employees to quickly and transparently access information on time off that they have banked, options to take leave for continuing education or to care for family members, and possible early retirement. The HR Excellence Awards have been presented by Human Resources Manager magazine since 2012 to recognize outstanding projects in personnel management.

]]>